Close Menu

TK inhibitors

The study found immunomodulatory and angiogenesis gene expression signatures, mutational profiles, and HLA types could help predict how patients respond to therapy.

BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.

Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.